Davey P, Rutherford D, Graham B, Lynch B, Malek M
Pharmacoeconomics Research Centre, Universities of Dundee.
Br J Gen Pract. 1994 Nov;44(388):509-13.
Several new antibacterial drugs have been introduced in the last 10 years with the aim of improved treatment of respiratory tract infection.
The study set out to use repeat consultations as a measure of the outcome of antibiotic treatment for respiratory tract infection, and to develop a simple model for discussion of the cost effectiveness of alternative antibiotic treatments.
All consultations to one practice during a single winter were reviewed by one general practitioner.
A total of 1140 patients had acute symptoms suggestive of respiratory infection. Of these, 899 patients (79%) were prescribed antibiotics at the first consultation and 160 of the 899 patients (18%) returned for one or more repeat consultations; only nine repeat consultations were due to adverse effects of the antibiotics prescribed. Only two patients were admitted to hospital for respiratory symptoms following initial antibiotic therapy and both patients had additional reasons for their admission. Using the highest estimates, the cost of a repeat consultation was found to be 28.54 pounds. These data were used to calculate how much more might be spent on more effective antibiotics at the first consultation. It would be difficult to justify increasing the cost of antibiotic treatment by more than 5 pounds per patient, even if the new treatment were 100% effective and all repeat consultations were due to treatment failure (5 pounds is equal to 28.54 pounds x 0.18, which is the maximum cost of a repeat consultation multiplied by the proportion of patients prescribed antibiotics who make repeat consultations).
From these results and a review of the literature it can be concluded that new antibacterial drugs will have to be carefully targeted if they are to prove cost effective in practice. Other methods for reducing repeat consultation merit investigation.
在过去十年中引入了几种新型抗菌药物,旨在改善呼吸道感染的治疗效果。
本研究旨在将重复就诊作为呼吸道感染抗生素治疗效果的一项衡量指标,并建立一个简单模型来讨论替代抗生素治疗的成本效益。
由一名全科医生对一个诊所单个冬季期间的所有就诊情况进行审查。
共有1140例患者出现提示呼吸道感染的急性症状。其中,899例患者(79%)在首次就诊时被开具了抗生素,899例患者中的160例(18%)回来进行了一次或多次重复就诊;只有9次重复就诊是由于所开抗生素的不良反应。初始抗生素治疗后仅有2例患者因呼吸道症状住院,且这两名患者住院还有其他原因。使用最高估计值,发现一次重复就诊的成本为28.54英镑。这些数据被用于计算在首次就诊时使用更有效的抗生素可能要多花费多少。即使新治疗100%有效且所有重复就诊均因治疗失败,要证明每位患者抗生素治疗成本增加超过5英镑是合理的也很困难(5英镑等于28.54英镑×0.18,即重复就诊的最高成本乘以开具抗生素后进行重复就诊的患者比例)。
从这些结果以及对文献的回顾可以得出结论,新型抗菌药物若要在实际应用中证明具有成本效益,就必须谨慎定位目标人群。其他减少重复就诊的方法值得研究。